---
stable_id: R-HSA-186786
display_name: Autophosphorylation of PDGF beta receptors
species: Homo sapiens
summary: 'Receptor dimerisation is key event in PDGF receptor activation. The intracellular
  regions of the receptors are juxtaposed which allows trans-phosphorylation between
  the two receptors in the complex.<br>The autophosphorylation site Y857 located inside
  the kinase domain of beta-receptor (PDGFRB) is important for activation of the kinase.
  This tyrosine is conserved in the alpha-receptor (PDGFRA), where it corresponsds
  to Y849, and in almost all other tyrosine kinase receptors. The other known autophosphorylation
  sites are localized outside the kinase domains of the alpha- and beta- receptors;
  of the 15( beta) or 16 (alpha) tyrosine residues in the intracellular, non-catalytic
  part of the beta- or alpha receptor, 11 and 10, respectively, are autophosphorylation
  sites (reviewed in Heldin et al, 1998).<br>PDGFRA and PDGFRB activity can be inhibited
  by binding to type I and type II tyrosine kinase inhibitors (reviewed in Roskoski,
  2018). Type I inhibitors such as crenolanib, avripatinib and pazopanib, bind to
  the active conformation of the receptor and inhibit trans-autophosphorylation (Ip
  et al, 2018; Evans et al, 2017; Davids et al, 2009; reviewed in Roskoski, 2018;
  Klug et al, 2018; Papadopoulos and Lennartsson, 2016).<br> '
---

# Autophosphorylation of PDGF beta receptors
**Reactome ID:** [R-HSA-186786](https://reactome.org/content/detail/R-HSA-186786)
**Species:** Homo sapiens

## Summary

Receptor dimerisation is key event in PDGF receptor activation. The intracellular regions of the receptors are juxtaposed which allows trans-phosphorylation between the two receptors in the complex.<br>The autophosphorylation site Y857 located inside the kinase domain of beta-receptor (PDGFRB) is important for activation of the kinase. This tyrosine is conserved in the alpha-receptor (PDGFRA), where it corresponsds to Y849, and in almost all other tyrosine kinase receptors. The other known autophosphorylation sites are localized outside the kinase domains of the alpha- and beta- receptors; of the 15( beta) or 16 (alpha) tyrosine residues in the intracellular, non-catalytic part of the beta- or alpha receptor, 11 and 10, respectively, are autophosphorylation sites (reviewed in Heldin et al, 1998).<br>PDGFRA and PDGFRB activity can be inhibited by binding to type I and type II tyrosine kinase inhibitors (reviewed in Roskoski, 2018). Type I inhibitors such as crenolanib, avripatinib and pazopanib, bind to the active conformation of the receptor and inhibit trans-autophosphorylation (Ip et al, 2018; Evans et al, 2017; Davids et al, 2009; reviewed in Roskoski, 2018; Klug et al, 2018; Papadopoulos and Lennartsson, 2016).<br> 
